Home
BIIB
BIIB News

Latest Biogen Inc. (BIIB) News on January 15, 2025

Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist

TipRanks

21 hours ago

Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist

Biogen bid for Sage does not change narrative, says BMO Capital

TipRanks

21 hours ago

Biogen bid for Sage does not change narrative, says BMO Capital

FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi

Benzinga

21 hours ago

FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi

Eisai and Biogen’s subcutaneous Leqembi set for FDA review

Pharmaceutical Technology

a day ago

Eisai and Biogen’s subcutaneous Leqembi set for FDA review

MT Newswires

a day ago

Biogen, Eisai Say Biologics License Application for Leqembi Accepted by US FDA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

GlobeNewswire

a day ago

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Biogen proposes acquisition of partner Sage Therapeutics

Pharmaceutical Technology

2 days ago

Biogen proposes acquisition of partner Sage Therapeutics

Biogen Offers to Buy Remaining Stake in Sage Therapeutics

Zacks

2 days ago

Biogen Offers to Buy Remaining Stake in Sage Therapeutics

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?

Benzinga

2 days ago

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?

Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen

Barrons.com

2 days ago

Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen

MT Newswires

2 days ago

SAGE Therapeutics Receives Unsolicited $7.22 Per Share Acquisition Proposal From Biogen

Biogen proposes to buy remaining stake in Sage in $442 million deal

Reuters

4 days ago

Biogen proposes to buy remaining stake in Sage in $442 million deal

MT Newswires

5 days ago

Wells Fargo Cuts Price Target on Biogen to $165 From $190, Maintains Equalweight Rating

Here’s Why ClearBridge Growth Strategy Sold Biogen (BIIB)

Insider Monkey

5 days ago

Here’s Why ClearBridge Growth Strategy Sold Biogen (BIIB)

Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets

BioPharma Dive

5 days ago

Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets

Alzheimer’s Drugs Eyed as Next Big Obesity-Like Opportunity

Bloomberg

5 days ago

Alzheimer’s Drugs Eyed as Next Big Obesity-Like Opportunity

Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)’s Struggles with Alzheimer’s and MS Challenges?

Insider Monkey

7 days ago

Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)’s Struggles with Alzheimer’s and MS Challenges?

MT Newswires

7 days ago

Truist Cuts Price Target on Biogen to $220 From $302, Keeps Buy Rating

MT Newswires

8 days ago

RBC Cuts Price Target on Biogen to $231 From $260, Keeps Outperform Rating

These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024

Motley Fool

11 days ago

These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024

MT Newswires

12 days ago

Guggenheim Adjusts Price Target on Biogen to $190 From $245, Maintains Buy Rating

MT Newswires

13 days ago

Biogen Shares Lower After Piper Sandler Downgrade

Investing.com

13 days ago

Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges

MT Newswires

13 days ago

Piper Sandler Downgrades Biogen to Neutral From Overweight

Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term

Zacks

14 days ago

Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term

The 5 worst performing stocks on the Nasdaq 100 in 2024

TheStreet

14 days ago

The 5 worst performing stocks on the Nasdaq 100 in 2024

Biogen Inc. (BIIB): Among the Cheap Healthcare Stocks to Buy Heading Into 2025

Insider Monkey

18 days ago

Biogen Inc. (BIIB): Among the Cheap Healthcare Stocks to Buy Heading Into 2025

Biogen Faces Multiple Analyst Downgrades in December 2024

GuruFocus.com

23 days ago

Biogen Faces Multiple Analyst Downgrades in December 2024

Investing.com

a month ago

BMO cuts rating on Merck and Biogen, on lack of near term catalyst

MT Newswires

a month ago

BMO Capital Downgrades Biogen to Market Perform From Outperform, Adjusts Price Target to $164 From $230

Investing.com

a month ago

Stifel downgrades Biogen on slow Alzheimer’s drug launch, uncertainty ahead

Netflix, Ford, Biogen: Trending tickers

Yahoo Finance Video

a month ago

Netflix, Ford, Biogen: Trending tickers

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks

a month ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

MT Newswires

a month ago

Stifel Downgrades Biogen to Hold From Buy, Adjusts Price Target to $175 From $275

CMS says private Medicare plans can’t automatically deny Biogen’s ALS drug

BioPharma Dive

a month ago

CMS says private Medicare plans can’t automatically deny Biogen’s ALS drug

Is Biogen Inc.'s (NASDAQ:BIIB) Stock Price Struggling As A Result Of Its Mixed Financials?

Simply Wall St.

a month ago

Is Biogen Inc.'s (NASDAQ:BIIB) Stock Price Struggling As A Result Of Its Mixed Financials?

Biogen reinstated with a Neutral at BofA

TipRanks

a month ago

Biogen reinstated with a Neutral at BofA

Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock

Zacks

a month ago

Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock

Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown

Benzinga

a month ago

Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown

Investing.com

a month ago

Biogen cut at Jefferies as '2025 has a tough setup'

MT Newswires

a month ago

Jefferies Downgrades Biogen to Hold From Buy, Adjusts Price Target to $180 From $250

MT Newswires

a month ago

Morgan Stanley Adjusts Price Target on Biogen to $192 From $204, Maintains Equalweight Rating

MT Newswires

a month ago

Biogen Says Leqembi Got Approval to Treat Early Alzheimer's Disease in Mexico

"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico

PR Newswire

a month ago

"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico

Morningstar Research

a month ago

Analyst Report: Biogen Inc.

MT Newswires

2 months ago

Biogen, Eisai Launch Alzheimer's Drug Leqembi in South Korea

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Zacks

2 months ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Why Biogen Inc. (BIIB) is One of the Cheapest Stocks to Buy on Robinhood?

Insider Monkey

2 months ago

Why Biogen Inc. (BIIB) is One of the Cheapest Stocks to Buy on Robinhood?

"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea

PR Newswire

2 months ago

"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea

Why Is Biogen Inc. (BIIB) Among the Worst Performing Healthcare Stocks in 2024?

Insider Monkey

2 months ago

Why Is Biogen Inc. (BIIB) Among the Worst Performing Healthcare Stocks in 2024?

Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy?

Investor's Business Daily

2 months ago

Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy?

Goldman Sachs: Biogen Inc. (BIIB) Is A Top Growth Investor Stock

Insider Monkey

2 months ago

Goldman Sachs: Biogen Inc. (BIIB) Is A Top Growth Investor Stock

Biogen price target lowered to $207 from $251 at Mizuho

TipRanks

2 months ago

Biogen price target lowered to $207 from $251 at Mizuho

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

Benzinga

2 months ago

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

MT Newswires

2 months ago

Mizuho Securities Adjusts Price Target on Biogen to $207 From $251

Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now

Insider Monkey

2 months ago

Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now

MT Newswires

2 months ago

Biogen, Partner Say Late-Stage Trial of Lupus Erythematosus Drug Candidate Met Primary Endpoint

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

GlobeNewswire

2 months ago

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026

Benzinga

2 months ago

Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026

Investing.com

2 months ago

Needham downgrades Biogen on slow growth of Alzheimer's drug

MT Newswires

2 months ago

Needham Downgrades Biogen to Hold From Buy

Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™

GlobeNewswire

2 months ago

Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™

Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now?

Insider Monkey

2 months ago

Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now?

Morningstar Research

2 months ago

Analyst Report: Biogen Inc.

MT Newswires

2 months ago

Baird Raises Biogen Price Target to $300 From $294, Maintains Outperform Rating

Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe

Zacks

2 months ago

Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe

European committee takes a second look at Alzheimer's drug and now says it should be approved

Associated Press Finance

2 months ago

European committee takes a second look at Alzheimer's drug and now says it should be approved

5 Healthcare Stocks to Buy in a Beaten-Up Sector

Barrons.com

2 months ago

5 Healthcare Stocks to Buy in a Beaten-Up Sector

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

PR Newswire

2 months ago

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease

MT Newswires

2 months ago

Biogen's Alzheimer's Disease Drug Gets Positive Opinion From Europe Regulators

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal

Zacks

2 months ago

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal

Investing.com

2 months ago

Citi initiates coverage on 5 new biotech stocks

RNA Stock Hits Record High on Entering the Cardiac Disease Space

Zacks

2 months ago

RNA Stock Hits Record High on Entering the Cardiac Disease Space

Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut

Zacks

2 months ago

Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut

Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View

Zacks

2 months ago

Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View

Here's Why Biogen Inc. (BIIB) is a Strong Value Stock

Zacks

2 months ago

Here's Why Biogen Inc. (BIIB) is a Strong Value Stock

Morningstar Research

2 months ago

Analyst Report: Biogen Inc.

Morningstar Research

2 months ago

Analyst Report: Biogen Inc.

Perrigo's Q3 Earnings Fall Short of Estimates, Sales View Updated

Zacks

2 months ago

Perrigo's Q3 Earnings Fall Short of Estimates, Sales View Updated

BIIB vs. MYGN: Which Stock Is the Better Value Option?

Zacks

2 months ago

BIIB vs. MYGN: Which Stock Is the Better Value Option?

MT Newswires

2 months ago

Argus Cuts Biogen's Price Target to $200 From $250

Argus Research

2 months ago

Analyst Report: Biogen Inc

Argus Research

2 months ago

Market Update: AMT, BIIB, CHH, GPN, UPS, APTV

Are Investors Undervaluing Biogen (BIIB) Right Now?

Zacks

2 months ago

Are Investors Undervaluing Biogen (BIIB) Right Now?

Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

2 months ago

Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

MT Newswires

2 months ago

Biogen, Eisai Submit Biologics License Application for Alzheimer's Subcutaneous Autoinjector to US FDA

Biogen Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

2 months ago

Biogen Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

MT Newswires

2 months ago

RBC Adjusts Biogen's Price Target to $260 From $269

Investing.com

2 months ago

Biogen down as Morgan Stanley cuts rating on sluggish Alzheimer’s drug launch

MT Newswires

2 months ago

Wells Fargo Adjusts Price Target on Biogen to $190 From $225

MT Newswires

2 months ago

Wedbush Adjusts Price Target on Biogen to $187 From $195

MT Newswires

2 months ago

Piper Sandler Adjusts Price Target on Biogen to $315 From $307

MT Newswires

2 months ago

Goldman Sachs Adjusts Price Target on Biogen to $290 From $320

MT Newswires

2 months ago

Barclays Adjusts Price Target on Biogen to $180 From $190

MT Newswires

2 months ago

Leerink Partners Adjusts Price Target on Biogen to $290 From $310

MT Newswires

2 months ago

Morgan Stanley Downgrades Biogen to Equalweight From Overweight, Adjusts Price Target to $204 From $285

MT Newswires

2 months ago

Morgan Stanley Downgrades Biogen to Equalweight From Overweight, Cuts Price Target to $204 From $285

Biogen Inc (BIIB) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic ...

GuruFocus.com

2 months ago

Biogen Inc (BIIB) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic ...

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

GlobeNewswire

2 months ago

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough.

Investor's Business Daily

3 months ago

Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough.

Share on Social Networks: